Replies to post #114788 on Biotech Values

[jbog]

vimantoo,

Of course that only works in the short run. I was originally talking about 3 quarters of m-enox as the sole generic before the reality that T-enox won't be coming sets in, and that is still a decent estimate. As MNTA's cash position builds and TEVA remains silent, MNTA market cap will rise.

In Pharma that's not always true. How long has Pfizer, Merck, Lilly or Bristol been under the weather because of their future patent cliff's? Also current Momenta's cash position, which is at historical highs hasn't provided any support.

The answer lies in what they do with their new found cash, and as of now I see nothing to get excited about.